SCHEMBL3601434

SCHEMBL3601434

Fc1ccc(-c2ccsc2)cn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 9/20 1.00
CYP2B6 P20813 5/20 1.00
CYP2E1 P05181 2/20 1.00
PDGFRB P09619 7/20 0.51
PDGFRA P16234 7/20 0.51
CYP3A4 P08684 3/20 0.51
CYP2C19 P33261 3/20 0.51
CYP2C9 P11712 1/20 0.48
HIF1A Q16665 1/20 0.42
CTSC P53634 1/20 0.41
KCNH2 Q12809 1/20 0.41
CYP17A1 P05093 1/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26104326 0.80 CYP2A6 (0.64) CYP2A6CYP2B6CYP2E1CYP3A4CYP2C19
SCHEMBL5499638 0.79 CYP2A6 (0.66) CYP2A6CYP2B6CYP2E1PDGFRBPDGFRA
SCHEMBL17027857 0.76 CYP2A6 (0.61) CYP2A6CYP2B6CYP2E1PDGFRBPDGFRA
SCHEMBL14438063 0.76 CYP2A6 (0.61) CYP2A6CYP2B6CYP2E1PDGFRBPDGFRA
SCHEMBL3831923 0.72 CYP2A6 (0.57) CYP2A6CYP2B6CYP2E1PDGFRBPDGFRA
SCHEMBL27989815 0.72 CYP2A6 (0.74) CYP2A6CYP2B6CYP2E1CYP3A4CYP2C19
SCHEMBL2125063 0.72 CYP2A6 (0.72) CYP2A6CYP2B6CYP2E1PDGFRBPDGFRA
SCHEMBL3609180 0.72 CYP2A6 (1.00) CYP2A6CYP2B6CYP2E1PDGFRBPDGFRA
SCHEMBL21123910 0.72 CYP2A6 (0.56) CYP2A6CYP2B6CYP2E1PDGFRBPDGFRA
SCHEMBL19933961 0.72 CYP2A6 (0.56) CYP2A6CYP2B6CYP2E1PDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8609708-B2 Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2013-12-17 US disclosed
US-20100298345-A1 SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2010-11-25 US disclosed
US-20100298345-A1 SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2010-11-25 US disclosed
US-20100298345-A1 SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2010-11-25 US disclosed
US-20100035917-A1 PYRROLO[2,3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS 1KK2 INHIBITORS GLAXO GROUP LIMITED (GB) 2010-02-11 US disclosed
US-20080188527-A1 Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer HUMAN BIOMOLECULAR RESEARCH INSTITUTE 2008-08-07 US disclosed
US-20080188527-A1 Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer HUMAN BIOMOLECULAR RESEARCH INSTITUTE 2008-08-07 US disclosed
US-20080188527-A1 Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer HUMAN BIOMOLECULAR RESEARCH INSTITUTE 2008-08-07 US disclosed
US-20080176891-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-07-24 US disclosed
US-20080146606-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-06-19 US disclosed
WO-2005066162-A1 SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2005-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176891-A1 NOVEL COMPOUNDS NFKBIA, IKBKG, IKBKE CYP2A6 3465/4885CYP2B6 3285/4885CYP2E1 2911/4885
US-20080188527-A1 Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer CYP2A13, CYP2A6, CYP2B6 CYP2A6 2/4885CYP2B6 3/4885CYP2E1 46/4885
US-20100035917-A1 PYRROLO[2,3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS 1KK2 INHIBITORS PLK2, PDXK, MAP4K2 CYP2A6 3881/4885CYP2B6 3148/4885CYP2E1 2633/4885
US-20080146606-A1 NOVEL COMPOUNDS NFKBIA, IKBKG, IKBKE CYP2A6 3465/4885CYP2B6 3285/4885CYP2E1 2911/4885
US-20100298345-A1 SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER CYP2A13, CYP2A6, CYP2B6 CYP2A6 2/4885CYP2B6 3/4885CYP2E1 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.